Related Experiment Videos
Glycine antagonist and NO synthase inhibitor protect the developing mouse brain against neonatal excitotoxic lesions
S Marret1, C Bonnier, J M Raymackers
1Service de Médecine Néonatale, University of Rouen Medical School, France.
Insights
Kynurenic acid and nitric oxide synthesis inhibitors protect the developing brain from excitotoxic injury, offering new strategies for cerebral palsy prevention. These findings clarify molecular mechanisms in neuroprotection.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Cerebral palsy prevention and immature brain neuroprotection are critical healthcare priorities.
- Perinatal brain lesions linked to cerebral palsy have multifactorial causes, including hypoxic/ischemic events and maternal infections.
- Excitotoxicity, mediated by N-methyl-D-aspartate receptors, is a key pathway for neural cell death in perinatal brain damage.
Purpose of the Study:
- To evaluate the neuroprotective effects of various pharmacological agents against ibotenate-induced excitotoxic brain lesions in developing mice.
- To elucidate molecular mechanisms underlying excitotoxic brain injury and identify potential therapeutic targets for cerebral palsy.
Main Methods:
- Developing mice (postnatal day 5) received ibotenate injections to induce excitotoxic lesions.
- Co-administration of pharmacological agents, including kynurenic acid, N(G)-nitro-L-arginine, zinc gluconate, and U74389F, was assessed for neuroprotective efficacy.
- Lesion severity was evaluated to determine the dose-dependent effects of the tested agents.
Main Results:
- Kynurenic acid (N-methyl-D-aspartate receptor glycine site antagonist) demonstrated a dose-dependent neuroprotective effect.
- N(G)-nitro-L-arginine (nitric oxide synthesis inhibitor) also provided dose-dependent neuroprotection against excitotoxic injury.
- Zinc gluconate and the free radical scavenger U74389F failed to protect the developing brain from ibotenate-induced damage.
Conclusions:
- Kynurenic acid and nitric oxide inhibition represent promising neuroprotective strategies for preventing cerebral palsy.
- These findings enhance understanding of excitotoxic pathways in the developing brain.
- Targeting specific molecular mechanisms, like N-methyl-D-aspartate receptor function and nitric oxide synthesis, may lead to novel cerebral palsy prevention therapies.
Abstract:
The prevention of cerebral palsy and neuroprotection of the immature brain continue to be health care priorities. The pathophysiology of perinatal brain lesions associated with cerebral palsy seems to be multifactorial and includes pre- and perinatal factors such as preconceptional events, hormone and growth factors deficiencies, maternal infections with production of cytokines, and hypoxic/ischemic perfusion failures. Excitotoxic cascade could represent a common pathway that leads to neural cell death and subsequent brain damage. Brain injuries induced by ibotenate, a glutamatergic analog, which are essentially mediated through the N-methyl-D-aspartate receptor, mimic some aspects of the white matter cysts and transcortical necrosis observed in human perinatal brain damage. The purpose of the present study was to assess the protective role of several pharmacological agents, administered in conjunction with ibotenate, against induced excitotoxic lesions. We injected ibotenate in the developing mouse brain 5 d postnatally, after the full settlement of neuronal layers. Co-treatment with kynurenic acid, an antagonist of the facilitating glycine site of the N-methyl-D-aspartate receptor, or with N(G)-nitro-L-arginine, an inhibitor of nitric oxide synthesis, induced a dose-dependent neuroprotective effect. Conversely, zinc gluconate, a blocking agent of the channel linked to the N-methyl-D-aspartate receptor, and a free radical scavenger (U74389F), were unable to protect the developing brain against excitotoxic attack. These data help to clarify some molecular mechanisms involved in excitotoxic lesions of the developing mouse brain and permit us to envision new strategies in the prevention of cerebral palsy.